Company intelligence / Profile preview
Shanghai Changsen Pharmaceutical
Shanghai, Shanghai Shi, Chinalwbp.sh ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Changsen Pharmaceutical has multiple small molecule programs targeting viral hepatitis, immune/inflammatory, and oncology indications. Their most advanced programs (LW-231 for chronic hepatitis B and LW-402 for moderate atopic dermatitis) are in Phase 2 development, with additional early-stage oncology assets (e.g., LW-347 targeting PDL1 in Phase 1)[5].
- Therapeutic areas
- Infectious DiseasesOncologyGastroenterologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Changsen Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Changsen Pharmaceutical.